Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × camrelizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 18 Carcinoma, Non-Small-Cell Lung 16 Stomach Neoplasms 15 Nasopharyngeal Carcinoma 13 Triple Negative Breast Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 11 Esophageal Squamous Cell Carcinoma 11 Breast Neoplasms 10 Esophageal Neoplasms 9 Colorectal Neoplasms 9 Uterine Cervical Neoplasms 8 Sarcoma 6 Melanoma 6 Recurrence 5 Neoplasm Metastasis 5 Small Cell Lung Carcinoma 4 Lung Neoplasms 4 Hodgkin Disease 4 Cholangiocarcinoma 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3 Osteosarcoma 3 Liver Neoplasms 3 Glioblastoma 3 Gestational Trophoblastic Disease 3 Biliary Tract Neoplasms 3 Solid Tumor 2 Rectal Neoplasms 2 Metastatic Gastric Adenocarcinoma 2 Lymphoma, Extranodal NK-T-Cell 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡